Skip to main content
. Author manuscript; available in PMC: 2011 Aug 9.
Published in final edited form as: Drug Resist Updat. 2010 Aug 9;13(4-5):109–118. doi: 10.1016/j.drup.2010.07.001

Table 2.

A list of CSCs involved in chemoresistance

Cancer stem cells CSCs surface markers Chemotherapeutic Drug Characteristics References
acute myeloid leukemia CD34+/CD38- Ara-C CSCs are chemotherapy resistant (Ishikawa et al., 2007; Saito et al., 2010)
Breast cancer CD29hi/CD24med CD44hi/CD24low Cisplatin; paclitaxel CSCs contribute to cisplatin and paclitaxel resistance (Shafee et al., 2008; To et al., 2010)
Chronic myelogenous leukemia CD34- Imatinib CSCs are resistant to imatinib (Lemoli et al., 2009)
Colon cancer CD133+ Oxaliplatin; 5-fluorouracil; cyclophosphami de; irinotecan CSCs are resistant to oxaliplatin and 5-FU due to induction of interleukin-4; resistant to cyclophosphamide due to production of Aldehyde dehydrogenase 1 activity. (Dylla et al., 2008; Fang et al., 2010; Ong et al., 2010; Todaro et al., 2007)
Glioblastoma CD133+ temozolomide, carboplatin, paclitaxel, and etoposide CSCs showed significant resistance to these chemotherapeutic agents (Liu et al., 2006)
Hepatocellular carcinoma Hoechst+ Doxorubicin; methotrexate CSCs showed significantly higher viability following treatment with doxorubicin or methotrexate (Zhang et al., 2010)
Osteosarcoma CD117+ Stro-1+ Doxorubicin CSCs showed drug-resistant properties and were enriched for CXCR4 and ABCG2 (Adhikari et al., 2010)
Ovarian cancer CD44+/CD24-CD133+/CD117+ Hoechst+ Carboplatin and paclitaxol; cisplatin CSCs markedly resistant to carboplatin and paclitaxol. CSCs resisted cisplatin due to high expression of ABCG2 (Hu et al., 2010; Shi et al., 2010b)
Pancreatic cancer CD44+ CD44+/CD24- Gemcitabine CSCs showed dramatic drug resistance to gemcitabine (Hermann et al., 2007; Hong et al., 2009)
Prostate cancer CD117+ABCG 2+ Arsenite; casplatin, paclitaxel, adriamycin, methotrexate CSCs showed resistance to arsenic-induced cytolethality due to higher expression of ABCC1 (Liu et al., 2010c; Tokar et al., 2010)
Small cell lung cancer CD133+/ABCG 2+ uPAR+ 5-FU; cisplatin and etoposide CSCs demonstrated multi-drug resistance. (Gutova et al., 2007; Wang et al., 2010b)